top of page


FDA grants accelerated approval to Johnson & Johnson's Rybrevant Faspro for advanced head and neck cancer
Johnson & Johnson's subcutaneous EGFR/MET-targeted therapy has received FDA accelerated approval for a defined population of adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma.

nuaxia
Nov 62 min read


FDA grants accelerated approval to Inovio Voceryq as first US plasmid DNA-based immunotherapy
The FDA has granted accelerated approval to Inovio's Voceryq, marking the first US authorisation of a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.

nuaxia
Nov 22 min read


FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.

nuaxia
Oct 222 min read


FDA grants accelerated approval to GSK Jemperli for MSI-H or dMMR locally advanced rectal cancer
The FDA has granted accelerated approval to GSK's Jemperli for previously untreated MSI-H or dMMR locally advanced rectal cancer, introducing a potentially organ-preserving immunotherapy approach.

nuaxia
Oct 202 min read


FDA grants accelerated approval to Etcamah combination for ESR1-mutated advanced breast cancer
The FDA has granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.

nuaxia
Sep 82 min read


FDA clears Wandercraft’s Eve self-balancing exoskeleton for personal use in adults with spinal cord injury
The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion.

nuaxia
Aug 142 min read


FDA grants accelerated approval to Zenbexus combination for previously treated multiple myeloma
The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM.

nuaxia
Aug 142 min read
bottom of page